Codeine
Market, by Indication (Pain Management, and Cough Management), by Age Group
(Adult and Pediatric), by Dosage Form (Tablet, Capsule and Solution/Syrup), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018
– 2026
Codeine is a drug of class known
as opioids, widely used in the treatment and management of mild to moderate
pain, severe pain, dry irritating cough, diarrhea, and cold and flu (when
combined with antihistamines and decongestants). Opioids interact with opioid
receptors in the brain and induce effects such as pain relief, relaxation,
pleasure, and contentment. Codeine is usually swallowed and comes in different
forms, including tablets, capsules, and solutions/syrups.
Codeine Market Drivers
Codeine is widely used in the
treatment and management of pain and cough. High prevalence of pain due to
increasing ageing population in key regions such as North America, and Asia-
Pacific is expected to significantly increase demand for codeine formulation
and drive global codeine market growth over the forecast period.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2297
For instance, according to the
data published by National Health Interview Survey (NHIS) in 2016, it was
estimated that around 20.4% (50.0 million) of the adults in the U.S. are
suffering from chronic pain and around 8.0% of adults in the U.S. (19.6 million)
had high impact chronic pain.
According to a study published by
the National Centre for Biotechnology Information (NCBI) in 2015, around 19.6%
of the individuals aged between 20 to 60 years were suffering from low back
pain worldwide.
Codeine Market Regional Analysis
North America codeine market is
expected to hold a dominant position in the global codeine market and to
account for largest market share over the forecast period, owing to high
presence of key players in the region and approval and launch of novel products
by them in the region.
For instance, in 2015, Tris
Pharma, Inc. received U.S. Food and Drug Administration approval and launched
its Tuzistra XR (codeine polistirex and chlorpheniramine polistirex),
extended-release oral suspension, CIII (DEA Schedule III) in the U.S. market.
Tuzistra XR is indicated for the treatment and relief of cough and symptoms
associated with upper respiratory allergies or a common cold in adults aged 18
years and older.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/codeine-market-2297
Codeine Market Restraint
Stringent regulations in key
regions for codeine formulation is expected to be a major factor restraining
growth of the codeine market in the near future. For instance, in February
2018, The Therapeutic Goods Administration reclassified codeine as prescription
only medicine in Australia, which was previously available as over-the-counter
medication. The fact behind this reclassification was that regular use of
medicines containing codeine may lead to its addiction.
Similarly, Health Canada also
proposed to ban non-prescription codeine sales in 2017. Reclassification of
codeine to prescription drugs is expected to hinder its sales and adoption and
is expected to restrain the global codeine market growth over the forecast
period
Codeine Market Key Players
Key players operating in global
codeine market include: Nexgen Pharma, Inc., Teva Pharmaceutical Industries
Ltd., Wraser Pharmaceuticals LLC, Larken Laboratories, Inc., Aurobindo Pharma
Limited, Sun Pharmaceutical Industries Limited, Tris Pharma Inc., and Johnson
& Johnson.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2297
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to emerging market
trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment